辅助治疗对Ⅰb_(2)~Ⅱa期宫颈癌患者的生存影响分析  

Effect of adjuvant therapy on survival of patients with stageⅠb_(2)-Ⅱa cervical cancer

作　　者：崔亚琴 贾宁 刘楷东 韩晓栋[1] 陈明晓[1] 李莉莉[1] 刘勇[1] 任俊丽[1] 康晓艳[1] 孙乃萍[1] 王雪荣 张继东[1] Cui Yaqin;Jia Ning;Liu Kaidong;Han Xiaodong;Chen Mingxiao;Li Lili;Liu Yong;Ren Junli;Kang Xiaoyan;Sun Naiping;Wang Xuerong;Zhang Jidong(Second Ward of Abdominal and Pelvic Radiotherapy,Shanxi Provincial Cancer Hospital,Shanxi Provincial Institute of Cancer Research,Taiyuan,030013,China)

机构地区：[1]山西省肿瘤医院山西省肿瘤研究所放疗腹盆二病区,太原030013

出　　处：《中国药物与临床》2022年第6期549-551,共3页Chinese Remedies & Clinics

摘　　要：目的分析新辅助化疗联合^(192)Ir后装近距离放疗、术后同步放化疗、术后辅助化疗对Ⅰb_(2)-Ⅱa期宫颈癌患者的生存影响。方法按配对设计收集2012年1月至2015年12月我院收治的有/无术前辅助治疗宫颈癌患者86对;分为2组,新辅助治疗治疗组接受新辅助化疗联合^(192)Ir后装近距离放疗后行手术治疗,手术组直接接受手术治疗;再对172例患者按是否行术后同步放化疗及是否行术后辅助化疗分组分析。结果新辅助化治疗组与手术组比较1、3、5年总生存时间,及复发、转移均差异无统计学意义(P>0.05);术后辅助化疗对3年总生存率差异无统计学意义(100%、96.5%,P>0.05);术后接受同步放化疗组3年总生存率大于未接受同步放化疗组(100%、91.8%,P<0.05)。结论新辅助化疗联合^(192)Ir后装近距离放疗、术后辅助化疗对Ⅰb_(2)-Ⅱa期宫颈癌患者的远期生存无影响;术后同步放化疗能提高该期患者远期生存时间。Objective To determine the effect of neoadjuvant chemotherapy combined with 192Ir brachytherapy,postoperative concurrent chemoradiotherapy and postoperative adjuvant chemotherapy on the survival of patients with stageⅠb_(2)-Ⅱa cervical cancer.Methods A paired design was used to includ 86 pairs of cervical cancer patients with/without preoperative adjuvant therapy admitted to our hospital between January 2012 and December 2015.One group received neoadjuvant chemotherapy combined with 192Ir brachytherapy followed by surgery(neoadjuvant treatment group),and the other group received surgical treatment directly(operation group).Then 172 patients were divided into two groups according to whether they received postoperative concurrent chemoradiotherapy and postoperative adjuvant chemotherapy.Results There were no significant differences in the overall survival time,recurrence and metastasis at 1,3 and 5 years after the treatment between the neoadjuvant chemotherapy therapy group and the operation group(all P>0.05).There was no significant difference in the 3-year overall survival rate between the neoadjuvant chemotherapy group and the operation group(100%vs 96.5%,P>0.05).The 3-year overall survival rate in the postoperative concurrent chemoradiotherapy group was higher than that in the non-concurrent chemoradiotherapy group(100%vs 91.8%,P>0.05).Conclusion Neoadjuvant chemotherapy combined with ^(192)Ir brachytherapy and postoperative adjuvant chemotherapy may not affect the long-term survival of patients with stageⅠb_(2)-Ⅱa cervical cancer.Postoperative concurrent chemoradiotherapy may improve the long-term survival time of patients in this stage.

关 键 词：肿瘤辅助治疗 宫颈肿瘤 影响因素分析 

分 类 号：R737.33[医药卫生—肿瘤]